L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX) vs. EXACT SCIENCES CORP (EXAS) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX) vs. EXACT SCIENCES CORP (EXAS) Stock Comparison & Valuation | Edwyn

Updated 2026-08-08 07:22 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

LHX screens as the fundamentally stronger business with positive earnings and cash-generation metrics, but the comparison to EXAS is not a clean valuation arbitrage because EXAS has higher revenue growth while LHX already trades near the top of its historical range.

Actionable Takeaway

If you believe LHX can continue compounding earnings at a high-teens quality level without a sharp multiple compression, then holding or adding makes sense because it combines positive margins, strong ROIC, and a 9/9 F-Score despite trading near the upper end of its historical range.

LHX is priced on profitable, mature defense-sector economics at 33.6x P/E and 2.5x P/S, while EXAS lacks earnings-based valuation due to negative net income. LHX’s current price of $286.67 sits above the midpoint of its historical band and below the top end of $315.34, which suggests valuation is elevated but not extreme relative to its own history.

Supporting Metrics

Key Risks

LHX valuation risk: 33.6x P/E leaves limited room for disappointment if growth slows.
DCF downside risk: the $111.50-$150.85 DCF range is far below the current $286.67 price.
EXAS comparison risk: EXAS’s 17.7% revenue growth means LHX is not the higher-growth name, even though LHX is far more profitable.